R&D News | pharmaphorum

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ claims full control of Caelum's AL amyloidosis drug in $5...

AstraZeneca's newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal that could be worth up to $500 million.

News

Bad news for Biohaven as verdiperstat flunks first phase 3 t...

Biohaven's key pipeline drug verdiperstat has failed to have any therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its lead indication – but

News

Parasitic biting insect on background of epidermis detail. Disgusting carrier of encephalitis, Lyme disease or babesiosis infections. Tick-borne diseases

Booster data backs Pfizer, Valneva Lyme disease vaccine

Prospects for Valneva's COVID-19 vaccine are up in the air, but another candidate partnered with Pfizer looks increasingly like it could fill the void of an effective shot for Lyme disease.

News

Sanofi abandons mRNA COVID jab, despite positive trial

Sanofi has said that it won't develop its mRNA-based vaccine for COVID-19 any further, even though it seemed to work in an early-stage trial, and will focus instead on another candidate par

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro

News

Roche builds evidence for Evrysdi's benefits in younger SMA ...

Roche has highlighted new data with its oral treatment for spinal muscular atrophy (SMA) – Evrysdi – showing its benefits when given to pre-symptomatic babies with the rare disease.

AZ claims full control of Caelum's AL amyloidosis drug in $5...

Bad news for Biohaven as verdiperstat flunks first phase 3 t...

Booster data backs Pfizer, Valneva Lyme disease vaccine

Sanofi abandons mRNA COVID jab, despite positive trial

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

Roche builds evidence for Evrysdi's benefits in younger SMA ...

Five indications added to Pharmacy First prescribing scheme

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks